Skip to main content

Advertisement

Log in

Effect of Artemisia annua extract on treating active rheumatoid arthritis: A randomized controlled trial

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the effect and safety of the complementary use of the extract of Artemisia annua L. (EAA) on treating active rheumatoid arthritis (RA).

Methods

A randomized controlled clinical trial was performed. All the 159 participates with active RA were randomly assigned to the control group (80 cases) and EAA group (79 cases) using concealed random allocation method. In the control group, patients were medicated with leflflunomide and methotrexate for 48 weeks; and patients in the EAA group were administrated with leflflunomide, methotrexate plus EAA (30 g/d). At the time points of 0, 12, 24 and 48 weeks, the clinical outcome measures, including objective pain score, tenderness score, number of painful joints, number of swollen joints, health assessment questionnaire (HAQ) score for quality of life, levels of serum rheumatoid factor (RF), anti-cyclic citrullinated protein antibodies (CCP-Ab), erythrocyte sedimentation rate (ESR), C reactive protein (CRP), visual analogue score for pain (VAS), and the overall effificacy were detected and recorded.

Results

The objective pain score, number of painful joints and ESR at 12 weeks, tenderness score and HAQ at 24 weeks, and the tenderness score, number of painfull joints, number of swollen joints, HAQ, CRP, RF and CCP-Ab at 48 weeks were signifificantly improved in the EAA group compared with the control group (P<0.01 or P<0.05). At 24 and 48 weeks, the overall effificacy of the EAA group was signifificantly higher than the control group (P<0.01). There were signifificantly higher withdrawal rate of corticosteroids within 12 weeks post-treatment and lower incidence rate of adverse effects in the EAA group compared with the control group (P<0.01 or P<0.05).

Conclusion

EAA plus methotrexate and leflflunomide were more effective and safer than the routine use of methotrexate and leflflunomide in the treatment of active RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J. Incidence of rheumatoid arthritis in Sweden—a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res (Hoboken) 2012;65:870–878.

    Article  Google Scholar 

  2. Tobon GJ, Youinou P, Saraux A. The environment, geoepidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 2010;35:10–14.

    Article  PubMed  Google Scholar 

  3. Xu C, Wang X, Mu R, Yang L, Zhang Y, Han S, et al. Societal costs of rheumatoid arthritis in China: a hospital-based crosssectional study. Arthritis Care Res (Hoboken) 2013;66:523–531.

    Article  Google Scholar 

  4. Dowman B, Campbell RM, Zgaga L, Adeloye D, Chan KY. Estimating the burden of rheumatoid arthritis in Africa: a systematic analysis. J Glob Health 2012;2:20406.

    Article  Google Scholar 

  5. Tarride JE, Haq M, Nakhai-Pour HR, O'Reilly DJ, Xie F, Dolovich L, et al. The excess burden of rheumatoid arthritis in Ontario, Canada. Clin Exp Rheumatol 2013;31:18–24.

    PubMed  Google Scholar 

  6. Yang M, Xiao CH, Wu QF, Niu MC, Yao Q, Li KQ, et al. Anti-inflammatory effect of Sanshuibaihu Decoction may be associated with nuclear factor-kappa B and p38 MAPK alpha in collagen-induced arthritis in rat. J Ethnopharmacol 2010;127:264–273.

    Article  PubMed  Google Scholar 

  7. Verschueren PC, Lories RJ, Daans M, Theate I, Durez P, Westhovens R, et al. Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:117–123.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang P, Li J, Han Y, Yu XW, Qin L. Traditional Chinese medicine in the treatment of rheumatoid arthritis: a general review. Rheumatol Int 2010;30:713–718.

    Article  PubMed  Google Scholar 

  9. Shakir L, Hussain M, Javeed A, Ashraf M, Riaz A. Artemisinins and immune system. Eur J Pharmacol 2011;668:6–14.

    Article  CAS  PubMed  Google Scholar 

  10. Wang JX, Tang W, Zhou R, Wan J, Shi LP, Zhang Y, et al. The new water-soluble artemisinin derivative SM905 ameliorates collagen-induced arthritis by suppression of inflammatory and Th17 responses. Br J Pharmacol 2008;153:1303–1310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cuzzocrea S, Saadat F, Di Paola R, Mirshafiey A. Artemether: a new therapeutic strategy in experimental rheumatoid arthritis. Immunopharmacol Immunotoxicol 2005;27:615–630.

    Article  CAS  PubMed  Google Scholar 

  12. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, et al. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-κB activation. FEBS Lett 2003;552:141–144.

    Article  CAS  PubMed  Google Scholar 

  13. Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP. SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages. Acta Pharmacol Sin 2009;30:1428–1435.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Konkimalla VB, Blunder M, Korn B, Soomro SA, Jansen H, Chang W, et al. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 2008;19:184–191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Li B, Li J, Pan X, Ding G, Cao H, Jiang W, et al. Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-alpha release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation. Int Immunopharmacol 2010;10:344–350.

    Article  CAS  PubMed  Google Scholar 

  16. Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, et al. Antimalarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) 2007;46:920–926.

    Article  CAS  Google Scholar 

  17. Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, et al. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol 2009;9:1509–1517.

    Article  CAS  PubMed  Google Scholar 

  18. Prato M, Gallo V, Giribaldi G, Aldieri E, Arese P. Role of the NFkappaB transcription pathway in the haemozoin-and 15-HETEmediated activation of matrix metalloproteinase-9 in human adherent monocytes. Cell Microbiol 2010;12:1780–1791.

    Article  CAS  PubMed  Google Scholar 

  19. Zhu C, Xiong Z, Chen X, Peng F, Hu X, Chen Y, et al. Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-kappaB pathway in microglia cells. PLoS One 2012;7:e35125.

    Article  Google Scholar 

  20. Cui XJ, Wang YY, Hou XQ, Pan L, Fu JX. Clinical observation of artesunate in treating rheumatoid arthritis. Chin J Hospit Pharm (Chin) 2007;27:645–647.

    Google Scholar 

  21. Wei S, Xu GG. Clinical observation of artesunate in treating rheumatoid arthritis. Shanxi Med J (Chin) 2008;37:457–458.

    Google Scholar 

  22. Gu WH. Clinical trial of the combined effect of Artemisia annua and methotrexate in treating rheumatoid arthritis. Contempor Med (Chin) 2011;17:155–156.

    Google Scholar 

  23. Zhou R. Clinical observation on treating rheumatoid arthritis with Artemisia annua plus methotrexate. Clin J Chin Med (Chin) 2011;3:24.

    Google Scholar 

  24. Li Y, Zhou JG, Yu XJ, Hu JP, Wu TT. Clinical study on rheumatoid arthritis treated with Abrotani Herba and methotrexat. China Pharmaceut (Chin) 2011;20:3–4.

    Google Scholar 

  25. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2012;51(Suppl 6):vi5–9.

    Google Scholar 

  26. Son KM, Song SH, Lim SK, Seo YI, Kim HA. Characteristics of patients with rheumatoid arthritis in clinical remission: the many aspects of DAS28 remission. Clin Exp Rheumatol 2012;30:947–950.

    PubMed  Google Scholar 

  27. Ranganath VK, Khanna D, Paulus HE. ACR remission criteria and response criteria. Clin Exp Rheumatol 2006;24(Suppl 43):S14–S21.

    Google Scholar 

  28. Smolen JS, Landew R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheumatc Diss 2010;69:964–975.

    Article  CAS  Google Scholar 

  29. O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010;69:1823–1826.

    Article  PubMed  Google Scholar 

  30. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthopaed Nurs 2010;29:260–275.

    Article  Google Scholar 

  31. Umicevic Mirkov M, Coenen MJ. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics 2013;14:425–444.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We are grateful to all the participants and staffs in the trial.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Min Yang.

Additional information

Supported by the National Natural Science Foundation of China (No. 810726), the Scientific Research Grants Program of Sichuan Provincial Administration of Traditional Chinese Medicine (No. 2012-E-063), the "Twelfth Five-Year Plan" Scientific Research Funds Project of Chinese PLA (No. BWS11J067), and the Hospital Program Fund for Research Talents (No. 2013YG-B007)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, M., Guo, My., Luo, Y. et al. Effect of Artemisia annua extract on treating active rheumatoid arthritis: A randomized controlled trial. Chin. J. Integr. Med. 23, 496–503 (2017). https://doi.org/10.1007/s11655-016-2650-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-016-2650-7

Keywords

Navigation